You are viewing a historical snapshot of India (NSE / BSE). These figures are a preview to show what TradeTidings covers. Live, continuously updated India sentiment and stock impact is a Pro feature.
Get live India data with ProDr. Reddy's Laboratories Ltd. (DRREDDY)
17 stories published on DRREDDY since June 2026. See all coverage.
News sentiment trend
Counts of positive, neutral, and negative news items over the last 90 days. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Sentiment timeline
How news sentiment on Dr. Reddy's Laboratories Ltd. (DRREDDY) has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
Why this reading
The recent items weighing most on this reading, by direction and influence.
Dr Reddy’s reports muted Q1FY27 results, net profit drops 69%
Direct news · High influence · Short term
Dr. Reddy's Q1 PAT Plunges 69%; US Generics Pricing Weighs Heavy
Direct news · High influence · Long term
Nifty Pharma Index Falls Nearly 2% on Trump Tariff Plan for Generic Drugs
Direct news · Medium influence · Long term
Dr Reddy's Stock: Company Halts Semaglutide API Over Impurity Issue
Direct news · Medium influence · Short term
Dr Reddy's Stock: Company Targets 6 to 7 Million Semaglutide Pens in FY27
Direct news · Medium influence · Long term
Direct news
The most recent stories naming DRREDDY directly, across all of our coverage.
Dr Reddy’s reports muted Q1FY27 results, net profit drops 69%
Dr. Reddy's Q1 PAT Plunges 69%; US Generics Pricing Weighs Heavy
Nifty Pharma Index Falls Nearly 2% on Trump Tariff Plan for Generic Drugs
Dr Reddy's Stock: Company Halts Semaglutide API Over Impurity Issue
Dr Reddy's Stock: Company Targets 6 to 7 Million Semaglutide Pens in FY27
Dr Reddy's Semaglutide Supply Disruption Raises Growth Concerns
Dr Reddy's Stock in Focus as Semaglutide Sales Halted and FY27 Target Cut
Axis Bank, Dr Reddy's, Hindalco and Nestle India Among Stocks With Dividend, Bonus or Split Actions on July 10
Dr Reddy's Pauses Semaglutide Supply Over Impurity Concerns
Dr Reddy's Semaglutide Supply Disruption to Run Until Late October on Quality Issue
Goldman Sachs Turns Cautious on Dr Reddy's Among Its Pharma Picks
Dr Reddy's Biologics Site Gets 7 USFDA Observations After Pre-License Inspection
Indirect drivers in the news
Macro, commodity, FX and regulatory forces that have moved DRREDDY, with the stories behind each.
See the full picture
Sign up free to track DRREDDY, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track DRREDDY for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.